Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement

Study:

ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement. A Pilot Study

Rationale:

n/a

Purpose:

The primary aim is to determine the rate of major bleeding and blood clots when using enoxaparin as a bridge to oral blood thinning medication in patients who have undergone mechanical valve replacement.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Mechanical Valve Replacement
Warfarin Therapy
Drug: enoxaparin Phase 4

Verified by The Cleveland Clinic January, 2006

Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT00298285

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

Allan Klein, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site